乳腺癌合并肺結核治療1例報道_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

向艷梅 ¹ , 陳歡 ² , 王舒 ² , 王光輝 ² ,  倪青 ^1,2

1. ;
2. ;

Corresponding?author：

倪青, Email: 13985527762@163.com

Keywords：

乳腺癌; 肺結核; 新輔助治療; 手術治療; 病理學完全緩解

DOI：

10.7507/1007-9424.202111037

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 向艷梅, 陳歡, 王舒, 王光輝, 倪青. 乳腺癌合并肺結核治療1例報道. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(7): 951-952. doi: 10.7507/1007-9424.202111037 Copy

1.	林薇, 湯善宏, 曾維政, 等. 惡性腫瘤患者并發結核感染的風險研究. 國際檢驗醫學雜志, 2017, 38(24): 3415-3417.
2.	Akbulut S, Sogutcu N, Yagmur Y. Coexistence of breast cancer and tuberculosis in axillary lymph nodes: a case report and literature review. Breast Cancer Res Treat, 2011, 130(3): 1037-1042.
3.	Bromberg SE, Amaral PG. Tuberculosis axillary lymph node coexistent breast cancer in adjuvant treatment: case report. Einstein (Sao Paulo), 2015, 13(3): 423-425.
4.	Pujani M, Khan S, Hassan MJ, et al. Coexistence of metastatic breast carcinoma and primary tuberculosis in axillary lymph nodes: a report of a rare case. Breast Dis, 2015, 35(3): 195-198.
5.	Baslaim MM, Al-Amoudi SA, Al-Ghamdi MA, et al. Case report: breast cancer associated with contralateral tuberculosis of axillary lymph nodes. World J Surg Oncol, 2013, 11: 43. doi: 10.1186/1477-7819-11-43.
6.	中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會（CSCO）乳腺癌診療指南2020. 北京: 人民衛生出版社, 2020.
7.	Vriens BEPJ, Vriens IJH, Aarts MJB, et al. Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. Breast Cancer Res Treat, 2017, 165(3): 593-600.
8.	Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17(6): 791-800.
9.	Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol, 2020, 6(3): e193692. doi: 10.1001/jamaoncol.2019.3692.
10.	Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol, 2018, 29(7): 1497-1508.
11.	中國乳腺癌新輔助治療專家組. 中國乳腺癌新輔助治療專家共識(2019年版). 中國癌癥雜志, 2019, 29(5): 390-400.

1. 林薇, 湯善宏, 曾維政, 等. 惡性腫瘤患者并發結核感染的風險研究. 國際檢驗醫學雜志, 2017, 38(24): 3415-3417.
2. Akbulut S, Sogutcu N, Yagmur Y. Coexistence of breast cancer and tuberculosis in axillary lymph nodes: a case report and literature review. Breast Cancer Res Treat, 2011, 130(3): 1037-1042.
3. Bromberg SE, Amaral PG. Tuberculosis axillary lymph node coexistent breast cancer in adjuvant treatment: case report. Einstein (Sao Paulo), 2015, 13(3): 423-425.
4. Pujani M, Khan S, Hassan MJ, et al. Coexistence of metastatic breast carcinoma and primary tuberculosis in axillary lymph nodes: a report of a rare case. Breast Dis, 2015, 35(3): 195-198.
5. Baslaim MM, Al-Amoudi SA, Al-Ghamdi MA, et al. Case report: breast cancer associated with contralateral tuberculosis of axillary lymph nodes. World J Surg Oncol, 2013, 11: 43. doi: 10.1186/1477-7819-11-43.
6. 中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會（CSCO）乳腺癌診療指南2020. 北京: 人民衛生出版社, 2020.
7. Vriens BEPJ, Vriens IJH, Aarts MJB, et al. Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. Breast Cancer Res Treat, 2017, 165(3): 593-600.
8. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17(6): 791-800.
9. Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol, 2020, 6(3): e193692. doi: 10.1001/jamaoncol.2019.3692.
10. Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol, 2018, 29(7): 1497-1508.
11. 中國乳腺癌新輔助治療專家組. 中國乳腺癌新輔助治療專家共識(2019年版). 中國癌癥雜志, 2019, 29(5): 390-400.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

乳腺癌合并肺結核治療1例報道

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content